Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

FAMILIES USA FOUNDATION INC

Filed by FAMILIES USA FOUNDATION, INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 18, 2025
Income
Not reported
Expenses
$17,000.00
Filing UUID
f095788f-0cd7-4449-94c9-8b59d0f00580
Termination date
Not reported

Expense method: B

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

S. 916Stop Shackling and Detaining Pregnant Women ActTo safeguard the humane treatment of pregnant and postpartum women by ensuring the presumption of release and prohibitingshackling, restraining, and other inhumane treatment, and for other purposes. TBDEqual Access to Abortion Coverage in Health Insurance Act (EACH Act) This bill requirescoverageforabortioncare through publichealthinsurance programs,including Medicaid, Medicare, and the ChildrensHealthInsurance Program, as well asinsurance plans for federal employees. Further,abortioncare must be available at federal, and federally supported,healthcare facilitiestoindividuals eligible for services at such facilities. S. 422Right to Contraception Act Toprotect an individuals abilitytoaccess contraceptives andtoengage incontraceptionandtoprotect a health care providers abilitytoprovide contraceptives,contraception, and information relatedtocontraception. TBDBlack Maternal Health MomnibusCritical funding for maternal health programs legislation to extend enhanced premium tax credits

MMM · Medicare/Medicaid

S.939Medicare Dental, Hearing, and Vision Expansion Act of 2025To amend title XVIII of the Social Security Act to provide coverage for dental and oral health care, hearing care, and vision care under the Medicare program. Legislation to advance site neutral payment reforms Legislation to ensure fair billing practice for items and services furnished by off-campus hospital locations a bill to task the Centers for Medicare & Medicaid Services (CMS) with establishing hybrid payments to reward primary care providers who provide the best care to their patients Budget resolution that would make massive cuts to Medicaid and other safety net programs, including policies around per capita caps, changing federal share (FMAP), provider taxes, work reporting requirements

PHA · Pharmacy

S.529Capping Prescription Costs Act of 2025To limit cost-sharing for prescription drugs, and for other purposes. S.527Prescription Pricing for the People Act of 2025To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes. S.1040Drug Competition Enhancement ActTo amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. S.1041Affordable Prescriptions for Patients ActTo amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1097Interagency Patent Coordination and Improvement Act of 2025To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. S.1095Stop STALLING ActTo enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. S.1096Preserve Access to Affordable Generics and BiosimilarsTo prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.